Cullin7: A new gene involved in liver carcinogenesis related to metabolic syndrome

Gut

Volumn 62, Issue 6, 2013, Pages 911-919

  Paradis, Valerie ^a,b   Albuquerque, Miguel ^a   Mebarki, Mouniya ^b   Hernandez, Lucie ^c   Zalinski, Stephane ^a   Quentin, Samuel ^c   Belghiti, Jacques ^a   Soulier, Jean ^c   Bedossa, Pierre ^a,b  

^a BEAUJON HOSPITAL   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c UNIVERSITÉ PARIS DIDEROT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CULLIN; CYCLIN D1;

ADULT; AGED; AMPLICON; APOPTOSIS; ARTICLE; BODY MASS; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CUL7 GENE; DOWN REGULATION; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

AGED; AGED, 80 AND OVER; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 6; CULLIN PROTEINS; CYCLIN D1; FEMALE; GENE EXPRESSION; HEPATITIS C; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84876940263     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302091     Document Type: Article

References (41)

1. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010;78:7-10.
2. El-Serag H, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
3. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011;140:1182-8.
4. Caldwell SH, Oelsner DH, Iezzoni JC, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9. (Pubitemid 29109578)
5. Angulo P. Non-alcoloholic fatty liver diseases. N Engl J Med 2002;346:1221-31.
6. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. (Pubitemid 34747534)
7. Adams LA, Lymp JF, Sauver JS, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048)
8. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S99-112.
9. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
10. Nair S, Mason A, Eason J, et al. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5. (Pubitemid 34700772)
11. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32.
12. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8. (Pubitemid 38182303)
13. Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and resource utilization for HCC: US perspective. Curr Med Res Opin 2010;26:2183-91.
14. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare Database. Hepatology 2011;54:463-71.
15. Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009;44:1190-4.
16. Guzman G, Brunt EM, Petrovic LM, et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6.
17. Bullock RE, Zaitoun AM, Aithal GP, et al. Association of non-alcoholic steatohepatitis without significant fibrosis with hepatocellular carcinoma. J Hepatol 2004;41:685-6. (Pubitemid 39297808)
18. Ertle J, Dechênel A, Sowa J-P, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2010;128:2436-43.
19. Regimbeau JM, Colombat M, Mogol P, et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69-73. (Pubitemid 38240104)
20. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 2009;49:851-9.
21. Farges O, Ferreira N, Dokmak S, et al. Changing trend in malignant transformation of hepatocellular adenoma. Gut 2011;60:85-9.
22. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenomas: an entity associated with increased body mass index and inflammation. Hepatology 2007;46:140-6. (Pubitemid 47171930)
23. Wong N, Lai P, Pang E, et al. Genomic aberrations in human hepatocellular carcinomas of different etiologies. Clin Cancer Res 2000;6:4000-6.
24. Kusano N, Shiraishi K, Kubo K, et al. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999;29:1858-62. (Pubitemid 29247061)
25. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005;41:1313-21. (Pubitemid 40770284)
26. Bedossa P, Poynard T, The French METAVIR Cooperative Study Group. An algorithm for grading activity in chronic hepatitis C. Hepatology 1996;24:289-93. (Pubitemid 26260021)
27. Kim S, Shago M, Kaustov L, et al. CUL7 is a novel antiapoptotic oncogene. Cancer Res 2007;67:9616-22. (Pubitemid 47621206)
28. Dias DC, Dolios G, Wang R, et al. CUL7: a DOC domain-containing cullin selectively binds Skp1 Fbx29 to form an SCF-like complex. Proc Natl Acad Sci USA 2002;99:16601-6. (Pubitemid 36034019)
29. Ong JP, Younossi ZM. Epidemiology and natural history of NAFLD and NASH. Clin Liver Dis 2007;11:1-16. (Pubitemid 46829973)
30. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7. (Pubitemid 36733754)
31. Sakakura C, Hagiwara A, Yamaguchi T, et al. Chromosomal aberrations in human hepatocellular carcinomas associated with hepatitis C virus infection detected by comparatives genomic hybridization. Br J Cancer 1999;80:2034-9. (Pubitemid 29391292)
32. Guan X-Y, Fang Y, Sham J, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 2000;29:110-16.
33. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972-8.
34. Sorrentino P, D'Angelo S, Ferbo U, et al. Liver iron excess in patients with hepatocellular carcinoma developed on non-alcoholic steato-hepatitis. J Hepatol 2009;50:249-51.
35. Ali S, Kasner J, Arai T, et al. Cul7/p185/p193 binding to simian virus 40 large T antigen has a role in cellular transformation. J Virol 2004;7:2749-57. (Pubitemid 38314334)
36. Beer DG, Kardia SL, Huang C, et al. Gene expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
37. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98:13790-5. (Pubitemid 33115977)
38. Singh D, Febbo PG, Roos K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9. (Pubitemid 41039166)
39. Le Faouder J, Laouirem S, Chapelle M, et al. Imaging mass spectrometry provides fingerprints for distinguishing hepatocellular carcinoma from cirrhosis. J Prot Res 2011;10:3755-65.
40. Okabe H, Lee SH, Phuchareon J, et al. A critical role for FBXWO and MAPK in cyclin D1 degradation and cancer cell proliferation. Plos One 2006;1:e128.
41. Arai T, Kasper JS, Skaar JR, et al. Targeted disruption of p185/Cul7 gene results in abnormal vascular morphogenesis. Proc Natl Acad Sci USA 2003;100:9855-60. (Pubitemid 37087031)